Gefitinib and erlotinib had an overall response rate of 0.5-0.74 million (56% to 74%) in advanced EGFR-mutated NSCLC, and the median PFS was 10 to 14 months [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.